Last reviewed · How we verify
Belatacept MI (more intensive)
Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.
Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation. Used for Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen).
At a glance
| Generic name | Belatacept MI (more intensive) |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | T-cell costimulation blocker |
| Target | CD80/CD86 (via CTLA4-Ig fusion protein) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Belatacept is a fusion protein (CTLA4-Ig) that blocks the CD28 costimulatory pathway by binding to CD80 and CD86 on antigen-presenting cells. This prevents the second signal required for full T-cell activation, thereby suppressing immune responses. The 'more intensive' formulation refers to a higher-dose regimen designed to provide enhanced immunosuppression in transplant recipients.
Approved indications
- Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen)
Common side effects
- Infection (including CMV, BK virus)
- Malignancy
- Acute rejection
- Hypertension
- Anemia
Key clinical trials
- Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant (PHASE3)
- Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) (PHASE3)
- Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney (PHASE2)
- Belatacept in Liver Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Belatacept MI (more intensive) CI brief — competitive landscape report
- Belatacept MI (more intensive) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI